4D Molecular Therapeutics Inc. Stock Price, News & Analysis

4D Molecular Therapeutics (Nasdaq: FDMT) announced that management will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference and will be available for one-on-one meetings.

The presentation is scheduled for Wednesday, Dec 3, 2025 at 2:35 p.m. ET. A live webcast will be available and archived copies will remain on the company's Investors website for up to one year.

4D Molecular Therapeutics (Nasdaq: FDMT) appointed Kristian Humer as Chief Financial Officer effective Nov 17, 2025. He will lead financial planning, capital allocation, corporate development and strategic initiatives as the company advances multiple Phase 3 programs and prepares for commercial readiness.

Humer brings more than 20 years of finance experience, including senior roles at Citi healthcare investment banking (2010–2021) and prior CFO positions at Foghorn Therapeutics and Viridian Therapeutics. He holds an MBA from Duke Fuqua and a BA (Hons) in accounting and economics from the University of Reading.

4D Molecular Therapeutics (Nasdaq: FDMT) announced on November 14, 2025 that its compensation committee granted 45,400 restricted stock units (RSUs) on November 11, 2025 to four new non-executive employees.

The awards were made under the company’s 2025 Employment Inducement Award Plan, which the board approved in February 2025 pursuant to Nasdaq Rule 5635(c)(4) to induce new hires to join the company.

4D Molecular Therapeutics (NASDAQ: FDMT) reported Q3 2025 results and operational highlights on Nov 10, 2025.

Key items: an $85 million upfront APAC license payment from Otsuka plus an expected ≥$50 million in cost sharing; eligibility for up to $336 million in milestones and tiered double-digit royalties; $372 million cash as of Sep 30, 2025; ~$93 million net proceeds from an equity offering; up to $11 million CF Foundation investment (first tranche $7.5M received).

Clinical: positive long-term PRISM Phase 1/2 wet AMD data (1.5–2 years), 4FRONT-1 >200 randomized and on track for Q1 2026 enrollment completion.

4D Molecular Therapeutics (Nasdaq: FDMT) said its management team will participate in a fireside chat and be available for one-on-one meetings at the Jefferies 2025 London Healthcare Conference.

The presentation is scheduled for Tuesday, Nov 18, 2025 at 9:00 a.m. GMT. A live webcast will be available, and archived copies will be posted for up to one year in the Investors section of the company's website.

4D Molecular Therapeutics (Nasdaq: FDMT) priced an underwritten common stock offering to raise approximately $100 million gross. The company will sell 8,385,809 common shares at $10.51 per share and, in lieu of shares for certain investors, 1,128,949 pre-funded warrants at $10.5099 each (exercise price $0.0001).

The offering is expected to close on November 7, 2025, subject to customary closing conditions; gross proceeds are before underwriting discounts, commissions and offering expenses. Leerink Partners, Evercore ISI and Cantor are joint book-running managers; RBC Capital Markets is co-manager.

4DMT (Nasdaq: FDMT) reported positive interim 1.5–3.5 year PRISM Phase 1/2 data for 4D-150 in wet AMD showing consistent maintenance of visual acuity, durable control of retinal anatomy, and large reductions in supplemental anti-VEGF injections through up to 2 years.

Key metrics include treatment-burden reductions up to 94% versus projected aflibercept, a dose response favoring the Phase 3 dose 3E10 vg/eye, a 2.8% rate of transient mild intraocular inflammation within 28 weeks, and Phase 3 enrollment > 200 patients with global 4FRONT-2 on track for completion in H2 2026.

4DMT (Nasdaq: FDMT) entered an exclusive license agreement with Otsuka to develop and commercialize 4D-150 for wet AMD and DME across the greater Asia-Pacific region, including Japan.

Key terms include an $85 million upfront cash payment, an expected ≥$50 million of cost sharing over three years for global development, up to $336 million in regulatory and commercial milestones, and tiered double-digit royalties on net sales in Otsuka’s territories. 4DMT retains development and commercialization rights outside APAC and will continue to lead global Phase 3 activities; APAC sites for 4FRONT-2 are expected to open by year-end, with Japan sites expected in January 2026.

4D Molecular Therapeutics (Nasdaq: FDMT) announced that on October 14, 2025 its compensation committee granted 25,450 Restricted Stock Units (RSUs) to three new non-executive employees under the company’s 2025 Employment Inducement Award Plan.

The inducement plan was approved by the board in February 2025 and is being used under Nasdaq Rule 5635(c)(4) to grant equity awards to attract new hires. The announcement identifies the grant date and plan authority but does not disclose recipient names, vesting terms, or share-count impact.